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Abstract
Oral administration of preformed specific antibodies is an attractive approach against infections of the digestive
system in humans and animals in times of increasing antibiotic resistances. Previous studies showed a positive
effect of egg yolk IgY antibodies on bacterial intoxications in animals and humans. Immunization of chickens with
specific antigens offers the possibility to create various forms of antibodies. Research shows that orally applied IgY’s
isolated from egg yolks can passively cure or prevent diseases of the digestive system. The use of these alternative
therapeutic drugs provides further advantages: (1) The production of IgY’s is a non-invasive alternative to current
methods; (2) The keeping of chickens is inexpensive; (3) The animals are easy to handle; (4) It avoids repetitive
bleeding of laboratory animals; (5) It is also very cost effective regarding the high IgY concentration within the egg
yolk. Novel targets of these antigen specific antibodies are Helicobacter pylori and also molecules involved in
signaling pathways in gastric cancer. Furthermore, also dental caries causing bacteria like Streptococcus mutans or
opportunistic Pseudomonas aeruginosa in cystic fibrosis patients are possible targets. Therefore, IgY’s included in
food for human consumption may be able to prevent or cure human diseases.
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The avian immune system
To protect the host against invading microorganisms
and exogenous antigens, the avian species have also
developed an immune system similar to mammals. The
avian immune system consists of primary and secondary
lymphoid organs. Thymus, located in the neck and Bursa
Fabricius, located adjacent to the cloaca, are primary
lymphoid organs. Secondary organs are spleen, caecal
tonsils, Harderian gland, bone marrow, lymph nodes, and
various lymphoid tissues e.g. lymphoid tissues associated
with mucosal surfaces (MALT); including bronchial-
associated lymphoid tissues (BALT), gut associated lymph-
oid tissues (GALT) and conjunctival associated lymphoid
tissues (CALT). The thymus is considered to be the pri-
mary lymphoid organ for T-cell differentiation and the
antibody-synthesizing B-cells are formed in the Bursa of
Fabricius, an organ which is unique in birds [1, 2]. The
plasma cell proliferation and memory B-cells are situated
within the spleen [3].
The avian immune system basically consists of two
types: first the innate, non-specific system and second
the acquired, specific system. The latter is mainly char-
acterized by specificity and memory. This system can be
distinguished into the cellular and non-cellular immune
response, once again.
The cellular response can be defined as those cells that
react with a high specificity to their specific antigen but
not including the cells involved in antibody production.
T-lymphocytes, as part of the cellular branch, recognize
processed antigens on antigen-presenting macrophages.
Among other tasks, T-cells are able to enhance or sup-
press the activity of B-cells, macrophages and T-helper
cells. Further T-cells can directly destroy foreign organ-
isms [4].
The non-cellular, also referred to as the humoral re-
sponse, includes plasma proteins, e.g. immunoglobulins
that passively circulate in blood or lymph, and antibody
producing B-lymphocytes. These cells are formed in the
embryonic liver, yolk sack and bone marrow. After matur-
ation in the Bursa Fabricius, B-cells move to the blood,
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spleen, caecal tonsils, bone-marrow, Harderian gland, and
thymus. T-helper cells are able to activate B-cells into plas-
mocytes. These plasmocytes are then able to secrete anti-
bodies (immunoglobulins) which are highly specific for
binding antigens. After re-exposing a chicken to the same
antigen a memory effect occurs, involving an increased
antibody production at a faster rate [5].
Immunoglobulin classes in birds in comparison to
mammals
Three classes of immunoglobulins in birds are known.
First described is the mammalian IgG which is analogous
to IgY and is mainly present in serum and egg yolk [6]. In
previous studies, IgY has been called IgG because of its
similar function and concentration in the serum. Now-
adays, this terminology has been found to be incorrect,
due to clear differences in molecular structure. Further-
more, recent studies describe the evolutionary relationship
between avian IgY’s and human IgE [7]. In addition, IgY’s
are also found in reptiles, amphibian and lungfish. The
comparion of different Immunoglobulin classes are shown
in Table 1.
Research has shown that other immunoglobulins in-
cluding chicken IgA and IgM have similar molecular
weight, structure and electrophoretic mobility compared
to mammalian IgA and IgM.
IgY antibodies make about 75 % of all immunoglobu-
lins. The serum concentrations of IgY, IgA, and IgM
have been reported to be 5.0, 1.25, and 0.61 mg.ml−1, re-
spectively [8].
In spite of functional homology between avian IgY and
mammalian IgG, there are differences in molecular
weight, structure and biochemical functions. They are
composed of two identical heavy and light chains bound
together with disulphide bonds. Furthermore, they own a
variable antigen-binding-site and a constant highly con-
served region. IgY’s are distinguished from IgG’s with
major heavy chains and therefore a higher molecular
weight. Moreover, avian IgY has a shorter and thus less
flexible hinge region than IgG [9]. It has also been sug-
gested that IgY’s have more hydrophobic molecules than
IgG antibodies and also have a lower isoelectric point [10].
IgY’s neither activate the complement system like IgG’s
[11] nor interact with rheumatoid factors in Immunoas-
says [10]. The structural differences between IgY’s and
IgG’s are shown in Fig. 1. Furthermore, IgY’s do not inter-
fere with protein A or C. This may not simplify the purifi-
cation but there are several methods for IgY extraction
from the egg yolk.
The antibody diversity in chicken is distinguished from
mammals and is based on gene conversion and somatic
hyperconversion.
Production of IgY’s starts with the immunization of
chickens
IgY’s are an inexpensive and an alternative form of poly-
clonal antibodies. For immunization the hens were injected
with specific antigens intramuscularly for several intervals.
Antibodies are transferred from hen to the offspring via the
latent stage of the egg. The immune-incompetent chick is
able to resist various infectious diseases due to the innate
immune system given from the hen. The transfer of IgY
antibodies from maternal serum to the egg yolk is analo-
gous to the cross-placental transmission in mammals [12].
During the last days of the embryonic development phase,
IgY is transported across the yolk sac membrane into the
embryonic bloodstream [13]. Recent studies show that the
transfer of IgY from serum to egg yolk is a receptor-
mediated process which allows a selective transfer of
antibodies from the maternal serum [14, 15]. Research sup-
ported that a specific sequence (His-Glu-Ala-Leu: HEAL)
in the FC-region and an intact hinge region are required
for transport. Changes in this amino acid sequence inhibit
IgY transport into the egg yolk. Roughly 4–6 days after
inoculation, IgY’s can be detected in the egg yolk [16, 17].
The antigen dose significantly influences the immune
response. Through renewed immunization the concen-
tration of antibodies can be strongly increased in the egg
yolk. This process avoids bleeding of animals, stress and
permits the harvest of large amounts of antibodies. Fur-
thermore, long-lasting high titre of IgY can be detected
in egg yolk [18].
Schade et al. [19] published a review about all IgY extrac-
tion and purification methods. The most frequent used
processes are with help of polyethyleneglycol [20], ammo-
nium or sodium sulfate [21, 22]. After purification IgY’s
show a high stability over a few months to a few years
under specified conditions [19].
Gene-specific antibodies make the complicated multi-
step process for specific antigen synthesis redundant [23].
Stability of avian IgY’s
For food fortification and the intestinal treatment to cure
or prevent diseases, it is necessary, to improve the heat
and pH resistance of IgY’s. Several studies have been con-
ducted to evaluate the stability of these antibodies. The
Table 1 Basic comparison of the adaptive immune system
between avian and mammals
Vertebrate class Immunoglobulin isotype
Mammals IgM IgD IgG IgE IgA
Avian species IgM IgY IgA
The adaptive immune system of avian and mammals is based on
immunoglobulins. Birds produce three types of immunoglobulins (IgM, IgY
and IgA), and the mammals five (IgM, IgD, IgG, IgE and IgA). In both cases the
acquired immunity includes T-cell receptors (TCRs), polymorphic MHC class I
and II molecules, primary and secondary lymphoid organs, rearrangement of
the recombination- activating gene (RAG) and antibody class switch
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activity of IgY may be reduced by gastric conditions,
particularly due to a low pH value [24]. Chicken anti-
bodies are quite stable against digestive enzymes trypsin
and chymotrypsin. Although there is a high loss of activity
through Pepsin under low pH conditions in a short time
[24, 25], IgY is stable at pH 4–9 and up to 65 °C in aque-
ous conditions. This resembles IgG, which is stable at
pH 3–10 and up to 70 °C [26, 27]. However, the resistance
of IgY to low pH conditions increases if high salt concen-
trations or stabilizing reagents e.g. sorbitol are present.
Xylitol does not have such an effect on heat resistance
[28]. Furthermore, the addition of sucrose increases the
resistance against low pH ranges, heat and pressure [29].
The egg yolk may be able to stabilize IgY under low pH
conditions and higher temperatures as well [30]. Several
studies also describe protein modifications and coating-
methods, respectively, and their positive effect against
inactivation through digestion, heat or acidic conditions.
Heat resistance of human IgG antibodies can be increased
with help of Polyethyleneglycol-modifications [31]. Encap-
sulation on IgY’s in liposomes has been detected to
stabilize antibodies against peptic hydrolysis under acidic
conditions [32]. Furthermore, the protective effect of
microencapsulation with chitosan–alginate on IgY during
gastric passage in vivo has been evaluated [33]. IgY was
reported to be stable for an extended durability for 14 weeks
except at temperatures over 50 °C [30, 34]. Gujral et al. ana-
lyzed the IgY antibody stability during 78 weeks of storage
at room temperature. In this case a combination with man-
nitol stabilized the IgY during the extended period [35].
Advantages for using IgY’s
The production of IgY’s is a non-invasive alternative to
current methods. The keeping of chickens is inexpensive
and the animals are easy to handle. It avoids repetitive
bleeding and pain of laboratory animals. Furthermore, it
is also very effective. The IgY-titre in the egg yolk of
immunized chickens remains very high for a long period
of time [18]. One egg yolk contains more antibodies
compared to the average isolated from the blood of im-
munized rabbits [36, 37].
IgY’s are able to prevent or cure human diseases as
described previously. IgY’s are not able to pass the
gastric barrier [28]. This offers various possibilities for
passive immunization in the digestive system against
pathogenic viruses and bacteria. But there are further
application possibilities, e.g. in diagnostic tests or pro-
tein purification processes. IgY’s are less acid- and
heat resistant than rabbit IgG [27, 38]. In 2002 Lee has
shown that it is possible to stabilize the pH resistance
with the help of sorbitol [28]. A further problem as
well is the molecular resistance against proteolytic
cleavage during the stomach passage. In 1993, Hatta
and colleagues published, that IgY activity was reduced
within a short time by pepsin, trypsin and chymotryp-
sin [26].
An advantage is that IgY’s neither activate the comple-
ment system nor bind to protein A and G, rheumatoid
factors or cell surface [9, 36]. The phylogenetic distance
between mammals and avian causes a high immune re-
sponse of birds to mammalian antigens. This increases
Fig. 1 Structure of avian IgY versus mammalian IgG. Both molecules contain two heavy and two light chains, which consist of a variable domain
(VH and VL) and four constant domains (CH1, CH2, CH3 and CH4), respectively. IgG has a longer hinge region, which makes it more flexible than
avian IgY
Müller et al. Nutrition Journal  (2015) 14:109 Page 3 of 7
the binding specificity of IgY which is shown through
immune diagnostics procedures like immunohistochem-
istry, ELISAs or immunofluorescence.
IgY antibodies and bacteria
In 1984 Marshall and Warren firstly described Helico-
bacter pylori—previously named Campylobacter pylor-
i—and its association with active chronic gastritis. They
characterized the bacterium as a spiral, gram-negative
organism with sheathed flagella. The organism is found
in the human stomach and induces inflammation of the
gastric mucosa [39]. It is known that H. pylori causes
chronic gastritis, peptic ulcers, gastric mucosa associ-
ated lymphoid tissue (MALT) lymphoma and gastric
cancer [40, 41]. Presently 70 % of all people in the world
are infected with H. pylori [42]. But only a small number
develop pathological symptoms. Previous studies
showed that the eradication of H. pylori inhibits the
reoccurrence of new gastric ulcers, cures several MAL-
Tomas and prevents peptic ulcers and gastric cancer
[40, 43].
Nowadays the infection with the bacterium can be
detected fast and often successfully medicated with spe-
cific antibiotic regimes which Wu et al. described in the
Review of evidence-based therapies against H. pylori.
But novel tools are necessary because there is a critical
increase of antibiotic resistances.
Previous studies showed a positive effect of specific IgY’s
against bacterial intoxications. The use of an oral therapy
with IgY’s offers the possibility of passive immunization.
There are several strategies of using IgY’s in host protec-
tion: a) inhibition of bacterial enzyme activity, b) toxin
neutralization, c) blocking cell adhesion of microorgan-
isms. The most effective way for passive immunization is
using IgY produced as a response to previously selected
characteristic bacterial antigens.
First trials for application of IgY’s in neonatal piglets
were already conducted in 1998. Threatening enteric
infections were treated with specific IgY antibodies
against E. coli K88+ [44]. Later these therapeutic options
were also validated with other E. coli, Salmonella, Cam-
pylobacter and Rotavirus strains [38, 45–48]. Enteric in-
fections caused by Salmonella are another problem in
chicken meat. Chalghoumi and colleagues published a
summarized review about the need of alternative methods
to prevent enteric infections in 2010. IgY’s may be a useful
and attractive tool to passively immunize chickens and
lower the infection rate in humans after consumption [5].
LeClaire et al. delivered chickens with staphylococcal
enterotoxin B (SEB) from Staphylococcus aureus. After
immunization they purified the egg yolk and treated
rhesus monkeys with the extract. At the same time the
monkeys were exposed to a lethal aerosolized dose of
SEB. All animals which were treated with specific anti-
SEB-IgY survived [49].
The actual transmission of H. pylori has never been
clarified. The H. pylori urease-enzyme may be mainly
responsible for colonization of human gastroduodenal
mucosa. This enzyme allows the survival in the acidic
gastric milieu. Urease creates a neutral microenviron-
ment around the organism. It catalyzes the cleavage of
urea to ammonia and carbon dioxide. This immediately
increases the ph value and allows the implantation in
the mucosa. The organism burrows into the mucosa to
reach the epithelial cells where a less acidic environment
is present [50]. Developed IgY’s against the whole-cell
lysate of a H. pylori strain inhibit growth and urease
activity of the organism in vitro [25]. In 2004 Horie and
colleagues demonstrated the efficiency of specific anti-
urease-IgY in designed drinking yogurt against H. pylori
infections. They showed that the oral intake of highly
specialized antibodies suppress the infection in humans.
Due to urease inhibition the adhesion to the mucosa
was also inhibited [51]. In 2009 Attallah and his group
developed a reliable model for H. pylori infection in
mice. Most cases of gastritis with inflammatory changes
were detected. They developed IgY-antibodies against the
cell lysate of a human pathogenic H. pylori strain in
chicken and treated diseased mice with it. Results demon-
strated that the passive immunized mice showed a signifi-
cant lower degree of infection and gastritis than untreated
animals [52]. Oral administration of preformed specific
antibodies is an attractive approach against infections of
the digestive system in humans and animals [9, 53].
Monoclonal IgY-antibodies in gastric cancer therapy
H. pylori is a significant risk factor for the genesis of
gastric cancer. As mentioned above, the eradication in-
hibits reoccurrence of gastric cancer. Changes in cellular
signaling cascades lead to cancer development. Cells prolif-
erate and grow uncontrolled quickly. The reasons for this
are somatic mutations leading to permanently activated
receptors and over-expression of receptors or ligands.
Novel therapies addressed these targets. Monoclonal anti-
bodies which are able to bind epitopes of the extracellular
domain of growth factor receptors were able to pre-
vent the receptor-ligand interaction and receptor
dimerization. There are possibilities influencing the signal
molecules, enzymes and intracellular receptors. The anti-
bodies used at present are chimeric, humanized biological
therapeutics [54]. It is conceivable that IgY’s administered
orally cause no allergic reaction and can be used as a
preventative therapy for gastric cancer caused by H.
pylori or as a general prevention against inflammation
caused by this bacteria. Additionally, because of its
high stability it can be used as a food supplement,
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which increases the access of this therapeutic tool
worldwide [55].
Novel therapies against dental caries and periodontitis
Dental caries are a result of oral bacteria like Streptococcus
mutans or Streptococcus sobrinus. To inhibit dental break-
down, a sugarless diet or use of fluoride is recommended.
In addition to antibiotics or other antibodies, IgY’s can be
applied against caries causing bacteria [56]. This was first
demonstrated positively in rats [57] and then in humans
as well [58].
In addition to caries, periodontitis also plays an import-
ant role in dental diseases. Porphyromonas gingivalis may
be the main cause for periodontitis [59]. In 2007 it was
demonstrated that IgY’s against a membrane-protein of P.
gingivalis inhibits the development of a pathogen biofilm
on the teeth surface and probably also following periodon-
tal diseases [60].
New target for egg yolk antibodies: Pseudomonas
aeruginosa
Cystic fibrosis (CF), an autosomal recessive hereditary
disease, affects mainly the lungs of patients among other
symptoms. Causes are mutations in the gene encoding
the cystic fibrosis transmembrane conductance regula-
tor (CFTR) protein [61]. This leads to a reduced transport
of chloride from exocrine cells and causes the development
of viscous mucus in the bronchia. Chronicle lung infections
by the opportunistic bacteria Pseudomonas aeruginosa (PA)
are the main causes of morbidity and mortality in CF pa-
tients. In 2003, Kollberg and colleagues published that rins-
ing with a solution of specific anti-PA IgY in the evening
may prevent the initial adhesion of the bacteria to the mu-
cosal surface of the oropharynx in CF patients [62]. At the
end of their study, all participants in the IgY treated group
were still without chronicle PA infections. It was demon-
strated that IgY could be used as a possible prophylaxis
treatment in CF patients and thus reduces the necessity of
frequent applications of antibiotics [62].
IgY’s as a new treatment approach for Celiac disease
Celiac disease (CD) is an autoimmune disease trig-
gered by the ingestion of gluten-containing grains in
susceptible individuals. Here, wheat gluten and similar
alcohol-soluble proteins are the causes responsible for
the development of intestinal damage. The disease is
characterized by a loss of absorptive villi and hyper-
plasia of the crypts. A gluten free diet is currently the
only accepted treatment for celiac disease [63]. In
2012 Gujral and colleagues evaluated specific IgY anti-
bodies against gliadin. As previously stated, purified
IgY antibodies are extremely sensitive to gastric condi-
tions and are rapidly inactivated by Pepsin under low
pH ranges. The development of appropriate sugar
protectants enables neutralization and the adsorption
of gliadin in both in vitro and in vivo [35]. This could
mean a revolution in the celiac disease treatment re-
gime and harbors new hope for all affected persons.
Conclusion
Using IgY in disease prevention and outlook
Today IgY technology is a fast spreading field in life sci-
ences. It may not be only a future vision anymore. IgY’s in
nose spray, cosmetics, body lotions, functional food e.g.
yogurt, powder supplement may be able to prevent or cure
human diseases. The use of IgY antibodies offers the possi-
bility for reducing antibiotics in the treatment of bacterial
infections of the digestive system. In addition, egg yolk anti-
bodies provide a new approach for attending Candida albi-
cans and intestinal parasites as well. Furthermore, IgY
treatment promises passive immunization in newborns and
immune compromised patients. Patients during chemo-
therapy do not produce sufficient amounts of antibodies in
response to vaccines. In this case passive immunization has
provided new opportunities and an alternative to current
treatment strategies. It may also be a new approach in ther-
apy for chronic inflammatory bowel diseases e. g. crohn’s
disease or ulcerative colitis. The local therapy with IgY anti-
bodies in the digestive system could replace the current sys-
temic treatment regime. Furthermore, IgY’s promise a new
field for all basic prophylactic treatment strategies.
There is a high potential for IgY antibodies in the
treatment of a variety of diseases and an even more pro-
spective future.
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